Salix's AIDS/HIV-related diarrhea drug Fulyzaq gets FDA nod

01/1/2013 | Reuters · American City Business Journals

Salix Pharmaceuticals' Fulyzaq, or crofelemer, has been approved by the FDA to treat diarrhea in HIV/AIDS patients undergoing antiretroviral therapy. This makes Fulyzaq, developed by Napo Pharmaceuticals, the first approved treatment for HIV/AIDS patients whose diarrhea is not caused by bacteria, virus or parasite.

View Full Article in:

Reuters · American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY